Bavarian Nordic in negotiations with the US authorities for the
further development of IMVAMUNE®
(Thomson Reuters ONE) - Kvistgaard, Denmark, August 24, 2009 - Bavarian Nordic A/S (OMX:BAVA) announced today that the US authorities have initiatednegotiations for a new contract to develop a freeze-dried version ofthe IMVAMUNE® smallpox vaccine. This potential new project will haveno influence on the ongoing RFP-3 BARDA (Biomedical Advanced Researchand Development Authority) contract for the procurement of 20 milliondoses of IMVAMUNE® and the licensure of the current liquid-frozenformulation, but represents an additional business opportunity.Earlier this year BARDA published a Broad Agency Announcement (BAA)soliciting proposals for the advanced development of medicalcountermeasures against chemical, biological, radiological andnuclear (CBERN) threats. In June, Bavarian Nordic submitted aproposal for the development of a freeze-dried formulation of theMVA-based smallpox vaccine, IMVAMUNE®. The proposal included thevalidation of the production process and the preclinical and clinicaldevelopment to support the use of the new freeze-dried formulation ofIMVAMUNE® following a declared emergency.A freeze-dried formulation of IMVAMUNE® offers various new advantagesin terms of increased shelf-life and improved stability of thevaccine compared to the current liquid-frozen formulation.Additionally, this will improve the cold-chain shipping logistics andstorage. These are all important criteria for governments around theworld that prioritise their bio terror preparedness.The new technology for freeze-drying the vaccine will also beapplicable for other MVA-BN® based vaccines.Anders Hedegaard, President & CEO of Bavarian Nordic said:"We arehappy about entering into negotiations with the US government on yetanother RFP for IMVAMUNE®. It clearly demonstrates their desire toexpand the ongoing collaboration beyond the existing contract todeliver 20 million doses of IMVAMUNE® and we look forward toexploring this exciting opportunity."Asger AamundChairmanContactAnders Hedegaard, President & CEO. Phone +45 23 20 30 64http://hugin.info/100065/R/1336540/318120.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 24.08.2009 - 08:02 Uhr
Sprache: Deutsch
News-ID 4988
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 341 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic in negotiations with the US authorities for the
further development of IMVAMUNE®"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
